Phase 2
N=16
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Bottom Line
View on ClinicalTrials.gov: NCT02932878 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcome: Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- DSXS topical (Drug)
- Age
- Pediatric, Adult · 2+ yrs
- Sex
- All
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Primary completion
- Apr 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients in the Study With HPA Axis Suppression |
1; 0; 10; 0 | — |
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
Eligibility Criteria
Inclusion Criteria
- Male or non pregnant, non lactating females
Exclusion Criteria
- Patients under 2 years of age
Data sourced from ClinicalTrials.gov (NCT02932878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.